Share

cover art for The rationale for CAR T-cell therapy in lupus

Lupus Hub

The rationale for CAR T-cell therapy in lupus

•

The Lupus Hub was pleased to speak with David Isenberg, University College London Hospitals NHS Foundation Trust (UCLH), London, UK. We asked, What is the rationale for treating lupus with CAR T-cell therapy?


During this interview, Isenberg discusses the unmet need for effective treatment strategies in patients with severe, treatment-refractory systemic lupus erythematosus (SLE) and the scientific rationale for using CAR T-cell therapy in these patients. He highlights its potential to achieve deep and sustained B-cell depletion and induce sustained remission in patients with highly aggressive disease. He also discusses the intensive nature of the treatment and the need for further evidence to establish its optimal timing, treatment setting, and clinical application.


Intended for healthcare professionals. This educational resource is independently supported by Autolus. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.

More episodes

View all episodes

  • How can established oncology CAR T-cell therapy pathways be adapted for rheumatology?

    03:51|
    The Lupus Hub was pleased to speak with Ruth Pepper, Royal Free Hospital and University College London Hospitals NHS Foundation Trust (UCLH), London, UK. We asked, How can established oncology CAR T-cell therapy pathways be adapted for rheumatology? During this interview, Pepper discusses how established approaches from hematology and oncology can be applied to the treatment of autoimmune diseases, including systemic lupus erythematosus (SLE). She describes how existing hematology infrastructure, expertise, and protocols for chimeric antigen receptor (CAR) T-cell therapy support the delivery of clinical trials in patients with treatment-refractory lupus. Pepper also highlights the importance of multidisciplinary collaboration between hematology, rheumatology, and nephrology teams in treatment delivery, monitoring for potential complications, and coordinating patient care. Intended for healthcare professionals. This educational resource is independently supported by Autolus. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.
  • Current evidence supporting obecabtagene autoleucel in lupus

    06:54|
    The Lupus Hub was pleased to speak with David Jayne, University of Cambridge, UK. We asked, What is the current evidence supporting obecabtagene autoleucel for the treatment of lupus, and what clinical trials are ongoing? During this interview, Jayne discussed the scientific rationale and emerging clinical evidence supporting CD19-directed CAR T-cell therapy for systemic lupus erythematosus (SLE) and lupus nephritis (LN). He highlighted the preliminary safety and efficacy data for obecabtagene autoleucel (obe-cel), ongoing clinical trials, and the opportunities and challenges associated with integrating CAR T-cell therapy into routine care. Intended for healthcare professionals. This educational resource is independently supported by Autolus. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.
  • What are the implications of the PHOENYCS GO trial for the SLE treatment landscape?

    06:13|
    The Lupus Hub was pleased to speak with Zahi Touma, University of Toronto and University Health Network, Ontario, CA. We asked, What are the implications of the PHOENYCS GO trial for the SLE treatment landscape? During this interview, Touma discusses the unmet need for therapies that provide broad and durable disease control in systemic lupus erythematosus (SLE) while minimizing glucocorticoid exposure, the mechanism of action of dapirolizumab pegol as a CD40 ligand (CD40L) inhibitor, and the clinical evidence supporting its development. He highlights findings from the phase III PHOENYCS GO trial (NCT04294667), including achievement of the primary endpoint and improvements across multiple measures of disease activity, disease control, fatigue, and glucocorticoid tapering, as well as an acceptable and manageable safety profile. Touma also discusses the ongoing PHOENYCS FLY trial (NCT06617325), which may further establish the role of dapirolizumab pegol in patients with moderate-to-severe disease. Intended for healthcare professionals. This educational resource is independently supported by Biogen MA, Inc. and UCB. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.
  • Guideline adherence in the management of lupus: Key challenges and potential solutions

    37:38|
    During the Lupus Hub Steering Committee (SC) Meeting held on June 19, 2025, key opinion leaders convened to discuss the key challenges associated with implementing guidelines for systemic lupus erythematosus (SLE) and lupus nephritis (LN) in clinical practice, as well as potential solutions. The meeting commenced with a presentation by the Lupus Hub SC Chair Ricard Cervera, who provided an overview of the key international guidelines, including the 2023 EULAR recommendations for SLE and LN, the 2024 ACR guidelines for LN, the 2025 ACR guidelines for SLE, the 2024 KDIGO guidelines for LN, and the 2023 EULAR guidelines for non-pharmacological management of SLE, and the need for a multidisciplinary approach to implement the guidelines in practice. The discussion featured other SC members (rheumatologists and immunologists), including Betty Diamond, Gaurav Gulati, Ioannis Parodis, Jill Buyon, Laurent Arnaud, and Manuel Francisco Ugarte-Gil, and four invited guest speakers – David D’Cruz (rheumatologist and thrombosis expert), David Jayne (nephrologist), Nathalie Costedoat-Chalumeau (autoimmune disease expert), and Onno Teng (nephrologist). Together, this multidisciplinary panel explored key barriers to the clinical implementation of guidelines and practical strategies to improve guideline adherence in routine settings.  This independent educational activity was supported by AstraZeneca. All content was developed independently. The funder was allowed no influence on the content of this activity.
  • LLDAS versus remission as treat-to-target goals

    20:40|
    During a meeting of the Lupus Hub Steering Committee, Ricard Cervera chaired a recorded discussion that also featured Murray Urowitz, Mandana Nikpour, Betty Diamond, James Cheng-Chung Wei, Manuel Francisco Ugarte-Gil, and Lyndsy Ambler. The topic of this discussion was Lupus Low Disease Activity State (LLDAS) versus remission as treat-to-target goals, and is the second part of our editorial theme on treatment goals.Ugarte-Gil and Nikpour open this discussion by providing the definition and differences between remission and LLDAS; highlighting remission as the absence of any disease activity, whilst LLDAS allows for a minimal amount. Acceptable disease activity in LLDAS is defined by a Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score of ≤4, Physician Global Assessment of ≤1, and a maximum corticosteroid dose of 7.5 mg daily. More information on these definitions can be found in our editorial theme article on treat-to-target in SLE.The discussion continues with an examination of these definitions, particularly around the absence of the patient experience, such as type 2 symptoms including fatigue, pain, and cognitive impairment. The limitations of both goals for a treat-to-target strategy are discussed and there is a suggestion that the definitions of these treatment goals may be refined to incorporate type 2 symptoms as and when there are therapeutic options that treat both type 1 and type 2 symptoms of the disease. Discussions continue around trials of LLDAS versus remission, and on to what the aim of treatment should be with newly diagnosed patients compared with those who have had disease for longer.This session concludes with an agreement that all treatment strategies should strive toward the best possible outcome for the patient, aiming for remission in all patients, plus a reduction in flares as much as possible.
  • How might deucravacitinib fit into the treatment pathway for patients with SLE?

    20:37|
    During the Lupus Hub Steering Committee meeting, key opinion leaders discussed how deucravacitinib might fit into the treatment pathway for patients with systemic lupus erythematosus (SLE). This recorded discussion was led by committee chair Ricard Cervera, and featured Murray Urowitz, Mandana Nikpour, Betty Diamond, James Cheng-Chung Wei, Manuel Francisco Ugarte-Gil, and Lyndsy Ambler.In this podcast, the committee members discuss how deucravacitinib, a TYK2 inhibitor, might fit into the current treatment algorithm for patients with SLE, using a case study as the basis for their discussions. The recently published phase II trial data of deucravacitinib for the management of SLE is discussed, alongside the potential for the introduction of new drugs to influence treatment strategies. The committee members also look at the pathogenesis of lupus and consider how combination treatments may impact symptom reduction and earlier cessation.
  • What do HCPs need to know about LN and the prevention of progression to ESRD?

    09:06|
    The Lupus Hub was pleased to speak to Murray Urowitz, University of Toronto, Toronto, CA. We asked, What do HCPs need to know about LN and the prevention of progression to end-stage renal disease (ESRD)?Urowitz begins by highlighting the incidence of ESRD in patients with lupus, with estimates ranging from 8% to 17% over 10 years. He then examines the factors associated with advancement to Grade 4 and 5 chronic kidney disease. He also presents data on the relationship between time to remission, number of flares in the first 5 years after initial remission, and the number of years a patient is on immunosuppressant therapy with the development of chronic kidney disease. Finally, he discusses how this data could inform lupus treatment and ultimately reduce the incidence of progression to ESRD.
  • Key communications on lupus at ACR 2022

    18:34|
    Following the American College of Rheumatology annual meeting (ACR Convergence 2022), the Lupus Hub was pleased to speak to Murray Urowitz, University of Toronto, Toronto, CA. We asked, What were the key communications on lupus at ACR 2022?In this podcast, Urowitz discusses five new therapies for lupus, as presented at ACR 2022, including deucravacitinib, litifilimab, zetomipzomib, telitacicept, and CAR T-cell agents. Urowitz outlines the mechanism of action for these therapies, highlighting the specific pathways targeted by different agents. Urowitz then provides data from clinical trials assessing these therapies and discusses their potential applications in lupus. Urowitz concludes by discussing two existing biologics, anifrolimab and voclosporin, and discussing 3-year follow up data in terms of the long-term efficacy and safety of these established treatments.